stockrow
Saturday 7 November 2026
Export ADXN’s income statement to Excel — free account
Addex Therapeutics Ltd. Sponsored ADR
ADXN Healthcare Biotechnology
Addex Therapeutics Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $36,200.00, down 92.1% from fiscal 2024.
- Revenue
- −86.0%
- EPS
- +25.8%
- Free cash flow
- −2.73%
Quarter to June 2026, against a year earlier
2.90
0.00
0.00%
Follow ADXN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | 1 | 7 | 3 | 4 | 3 | 1 | 2 | 0 | 0 | 0 | (28.2%) | 2 | 2 | — | +610.9% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 43.88 | +100.0 pt | ||||||
| EBT | (3) | (3) | (2) | 3 | (14) | (17) | (22) | (12) | (6) | (8) | (9) | +11.6% | ||||||
| EBT margin, % | 0.00 | (656.21) | (24.54) | 100.00 | (355.92) | (526.42) | (1,462.55) | (654.46) | (1,214.92) | (22,814.92) | 0.00 | (22,814.9) pt | ||||||
| Net income | (3) | 0 | 0 | 0 | (14) | (17) | (22) | (12) | 8 | (8) | (8) | +11.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.04 | 0.29 | 12.64 | 17.33 | 11.22 | 3.96 | 2.90 | 0.56 | 0.04 | 0.00 | n/m | |||||
| Earnings | (0.27) | (0.26) | (0.07) | (67.60) | (61.40) | (59.00) | (57.80) | (18.70) | 9.54 | (8.69) | (8.79) | +46.8% | ||||||
| Cash flow | (0.23) | (0.17) | 0.08 | (44.86) | (58.41) | (56.57) | (45.75) | (14.38) | (7.46) | (2.93) | (2.88) | +32.5% | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | (0.29) | (0.12) | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (0.23) | (0.17) | 0.08 | (44.86) | (58.70) | (56.69) | (45.75) | (14.39) | (7.46) | (2.93) | (2.88) | +32.5% | ||||||
| Book value | 0.02 | 0.11 | 1.72 | 119.61 | 70.07 | 65.13 | 13.67 | 2.06 | 13.44 | 6.43 | 2.36 | +91.2% | ||||||
| Shares, m | 11 | 13 | 23 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | (24.6%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.76 | 0.00 | 0.00 | 0.1 | |||||
| P/S | — | 0.00 | 0.00 | 0.00 | 15.47 | 11.21 | 3.44 | 2.17 | 12.47 | 30.07 | 12.90 | 8.3 | ||||||
| P/B | — | 1.30 | 1.30 | 1.30 | 3.82 | 1.93 | 0.99 | 3.06 | 0.52 | 1.20 | 1.23 | 1.7 | ||||||
| EV/Sales | — | 0.00 | 0.00 | 0.00 | 10.29 | 4.19 | (1.46) | (0.23) | 4.20 | 21.46 | 8.67 | 4.3 | ||||||
| EV/FCF | — | 0.00 | 0.00 | 0.00 | (3.04) | (0.83) | 0.13 | 0.05 | (0.32) | (1.88) | (0.67) | (0.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (3) | (2) | 2 | (10) | (13) | (16) | (17) | (9) | (6) | (3) | (3) | (0.1%) | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 | (22.7%) | ||||||
| Free cash flow | (3) | (2) | 2 | (10) | (13) | (16) | (17) | (9) | (6) | (3) | (3) | (0.1%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 0 | 2 | 41 | 28 | 17 | 19 | 5 | 1 | 3 | 1 | 0 | +4.2% | |||||
| Net debt | (1) | (3) | (43) | (33) | (20) | (22) | (7) | (4) | (4) | (2) | (1) | +4.0% | ||||||
| Shareholders’ equity | 0 | 1 | 40 | 26 | 16 | 19 | 5 | 1 | 11 | 6 | 2 | +44.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (129.31) | (405.76) | 0.00 | 0.00 | (118.36) | (72.73) | (130.77) | (169.81) | 92.65 | (81.98) | (117.46) | +47.3 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (27.18) | (56.24) | (141.24) | (56.2) pt | ||||||
| ROE | (389.80) | (422.59) | (8.11) | (44.84) | (65.47) | (98.49) | (184.19) | (366.08) | 130.66 | (96.99) | (154.91) | +292.8 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 17 | — | 27 | 28 | 24 | 23 | 2 | 3 | — | (21.9%) | |||||
| Revenue/emp, $m | — | 0.00 | 0.40 | 0.00 | 0.14 | 0.11 | 0.06 | 0.08 | 0.23 | 0.01 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Dec 2025 · fundamentals updated 2 Nov 2026
Addex Therapeutics Ltd. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PBLA Panbela Therapeutics Inc. | $3.4M | — (loss-making) | — | — | n/m | +66.23% (above 0%: growing) | — | 0.00% | Compare |
| ONCO Onconetix, Inc. | $3.2M | — (loss-making) | — (loss-making) | −83.94% (below 0%: shrinking) | n/m | −36.00% (below 0%: shrinking) | 25.15% | (15,969.59%) | Compare |
| SXTP 60 Degrees Pharmaceuticals Inc. | $3.2M | — (loss-making) | — (loss-making) | −32.48% (below 0%: shrinking) | n/m | −54.33% (below 0%: shrinking) | 27.32% | (1,092.40%) | Compare |
| ADXN Addex Therapeutics Ltd. Sponsored ADR | $3.1M | — (loss-making) | — (loss-making) | −85.95% (below 0%: shrinking) | n/m | −2.73% (below 0%: shrinking) | (2.67%) | 0.00% | |
| ERNA Ernexa Therapeutics Inc. | $3.0M | — (loss-making) | — (loss-making) | −94.12% (below 0%: shrinking) | n/m | −64.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MBIO Mustang Bio, Inc. | $3.0M | — (loss-making) | — | — | n/m | +27.78% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CMND Clearmind Medicine Inc. | $3.0M | — (loss-making) | — | — | n/m | −77.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KALA KALA BIO, Inc. | $3.0M | — (loss-making) | — (loss-making) | −86.31% (below 0%: shrinking) | n/m | +80.19% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BCAB BioAtla, Inc. | $2.9M | — (loss-making) | — (loss-making) | +4,233.33% (above 0%: growing) | n/m | +97.03% (above 0%: growing) | 100.00% | 3.49% | Compare |
| Median of peers | $3.0M | — | — | −83.94% | — | −4.11% | 25.15% | 0.00% |